dailyai.report

Biologic medicines rely on engineered proteins that are notoriously difficult to design. New AI tools now predict protein structures and interactions to reduce the high failure rate of drug candidates. MIT Tech Review highlights how these systems cut development costs. Researchers can now iterate designs digitally before entering expensive wet-lab testing phases.